Stockscreener 앱 받기
1.40
0.00%
0.00
전일 마감가:
$1.40
열려 있는:
$1.42
하루 거래량:
9,724
Relative Volume:
0.03
시가총액:
$115.88M
수익:
-
순이익/손실:
$-21.65M
주가수익비율:
-4.2156
EPS:
-0.3321
순현금흐름:
$-15.84M
1주 성능:
+6.87%
1개월 성능:
-2.78%
6개월 성능:
-27.84%
1년 성능:
+15.70%
1일 변동 폭
$1.39
$1.42
1주일 범위
$1.32
$1.475
52주 변동 폭
$0.9595
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
명칭
Cardiol Therapeutics Inc
전화
-
주소
-
CRDL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.40 | 115.88M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
173.09 | 77.71B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.59 | 43.05B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.37 | 42.23B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.34 | 19.33B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
151.21 | 15.26B | 2.24B | 385.90M | 440.10M | 3.73 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-26 | 개시 | ROTH MKM | Buy |
| 2024-04-22 | 개시 | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Cardiol Therapeutics to Present at Healthcare Conference, Highlighting Advances in Heart Disease Therapies - TipRanks
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile
Heart Disease Breakthrough: Cardiol Therapeutics Unveils Latest Research at Major Healthcare Summit - StockTitan
Cardiol Therapeutics to present at Oppenheimer Healthcare Conference - Proactive Investors USA
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Cardiol Therapeutics (NASDAQ:CRDL) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock By Investing.com - Investing.com Canada
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat
Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World
Pericarditis Drugs Market reached US$ 544.4 million in 2023 - openPR
Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat
Appendix 3Y x4 - Investing News Network
Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive
Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK
HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat
RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network
PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire
HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network
BPH Global receives funding commitment of A$100,000 - Investing News Network
Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat
David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World
Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World
Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com
CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
3 Penny Stocks Ready to Break Out in 2025 - MarketBeat
3 Penny Stocks Ready To Break Out In 2025 - Barchart
Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics Inc (CRDL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
0.68%
자본화:
|
볼륨(24시간):